Coherus Oncology (CHRS) Accumulated Expenses (2013 - 2026)
Coherus Oncology (CHRS) posted Accumulated Expenses of $15.2 million for Q1 2026, down 25.59% sequentially from $20.4 million in Q4 2025, and down 23.8% YoY from $20.0 million in Q1 2025.
Coherus Oncology (CHRS) Accumulated Expenses (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Accumulated Expenses for 14 years, with the latest figure at $15.2 million in Q1 2026.
- Quarterly Accumulated Expenses fell 23.8% year-over-year to $15.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.2 million (down 23.8% YoY) and the FY2025 annual result came in at $20.4 million, down 66.11% from the prior year.
- Accumulated Expenses retreated to $15.2 million in Q1 2026 per CHRS's latest filing, from $20.4 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $115.7 million in Q1 2024 and troughed at $11.0 million in Q2 2025.
- A 5-year average of $43.2 million and a median of $41.8 million in 2022 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 831.47% in 2024, then plunged 82.76% in 2025.
- Over 5 years, Accumulated Expenses stood at $50.1 million in 2022, then soared by 110.36% to $105.4 million in 2023, then tumbled by 42.79% to $60.3 million in 2024, then plunged by 66.11% to $20.4 million in 2025, then fell by 25.59% to $15.2 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $15.2 million, $20.4 million, and $13.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.85 Mn |
| Mar 31, 2026 | 15.20 Mn |
| Dec 31, 2025 | 20.43 Mn |
| Sep 30, 2025 | 13.10 Mn |
| Jun 30, 2025 | 11.02 Mn |
| Mar 31, 2025 | 19.95 Mn |
| Dec 31, 2024 | 60.29 Mn |
| Sep 30, 2024 | 15.76 Mn |
| Jun 30, 2024 | 61.04 Mn |
| Mar 31, 2024 | 115.71 Mn |
| Dec 31, 2023 | 105.39 Mn |
| Sep 30, 2023 | 18.08 Mn |
| Jun 30, 2023 | 41.81 Mn |
| Mar 31, 2023 | 12.42 Mn |
| Dec 31, 2022 | 50.10 Mn |
| Sep 30, 2022 | 85.99 Mn |
| Jun 30, 2022 | 41.79 Mn |
| Mar 31, 2022 | 45.89 Mn |
| Dec 31, 2021 | 22.01 Mn |
| Sep 30, 2021 | 18.79 Mn |